EGFR mutations and EGFR tyrosine kinase inhibitors

Lancet Oncol. 2015 Jul;16(7):746-8. doi: 10.1016/S1470-2045(15)00028-5. Epub 2015 Jun 4.

Authors

Valter Torri¹, Massimo Broggini¹, Marina Chiara Garassino²

Affiliations

¹ IRCCS Istituto di Ricerche Farmacologiche Mario Negri (IRFMN), Milan, Italy.
² Thoracic Oncology, Medical Oncology Department 1, Fondazione IRCCS Istituto Nazionale dei Tumori, 20129 Milano. Electronic address: marina.garassino@istitutotumori.mi.it.

PMID: 26051233
DOI: 10.1016/S1470-2045(15)00028-5

No abstract available

Publication types

Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung / drug therapy*
Female
Gene Expression Regulation, Neoplastic*
Genes, erbB-1 / genetics*
Humans
Lung Neoplasms / drug therapy*
Male
Mutation*
Quinazolines / administration & dosage*

Substances

Quinazolines